These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23094215)

  • 1. Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding.
    Yamada S; Kuraoka S; Osano A; Ito Y
    Int Neurourol J; 2012 Sep; 16(3):107-15. PubMed ID: 23094215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder.
    Yoshida A; Fujino T; Maruyama S; Ito Y; Taki Y; Yamada S
    J Pharmacol Sci; 2010; 112(2):142-50. PubMed ID: 20134113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment.
    Maruyama S; Tsukada H; Nishiyama S; Kakiuchi T; Fukumoto D; Oku N; Yamada S
    J Pharmacol Exp Ther; 2008 Jun; 325(3):774-81. PubMed ID: 18326811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography.
    Yoshida A; Maruyama S; Fukumoto D; Tsukada H; Ito Y; Yamada S
    Life Sci; 2010 Jul; 87(5-6):175-80. PubMed ID: 20598326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
    Maruyama S; Hasuike N; Suzuki K; Yamada S
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):463-71. PubMed ID: 18074121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice.
    Oki T; Sato S; Miyata K; Yamada S
    Br J Pharmacol; 2005 May; 145(2):219-27. PubMed ID: 15753946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.
    Ito Y; Oyunzul L; Yoshida A; Fujino T; Noguchi Y; Yuyama H; Ohtake A; Suzuki M; Sasamata M; Matsui M; Yamada S
    Eur J Pharmacol; 2009 Aug; 615(1-3):201-6. PubMed ID: 19446545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine--a new bladder-selective antimuscarinic agent.
    Nilvebrant L; Andersson KE; Gillberg PG; Stahl M; Sparf B
    Eur J Pharmacol; 1997 May; 327(2-3):195-207. PubMed ID: 9200560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
    Yamada S; Seki M; Ogoda M; Fukata A; Nakamura M; Ito Y
    J Pharmacol Exp Ther; 2011 Feb; 336(2):365-71. PubMed ID: 21047953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland.
    Kobayashi F; Yageta Y; Segawa M; Matsuzawa S
    Arzneimittelforschung; 2007; 57(2):92-100. PubMed ID: 17396619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
    Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
    Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
    Oki T; Toma-Okura A; Yamada S
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of central muscarinic receptor binding activity by oxybutynin, tolterodine and darifenacin used to treat overactive bladder.
    Oki T; Kageyama A; Takagi Y; Uchida S; Yamada S
    J Urol; 2007 Feb; 177(2):766-70. PubMed ID: 17222678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder.
    Oki T; Kimura R; Saito M; Miyagawa I; Yamada S
    J Urol; 2004 Nov; 172(5 Pt 1):2059-64. PubMed ID: 15540789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task.
    Kobayashi F; Yageta Y; Yamazaki T; Wakabayashi E; Inoue M; Segawa M; Matsuzawa S
    Arzneimittelforschung; 2007; 57(3):147-54. PubMed ID: 17469649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
    Sinha S; Gupta S; Malhotra S; Krishna NS; Meru AV; Babu V; Bansal V; Garg M; Kumar N; Chugh A; Ray A
    Br J Pharmacol; 2010 Jul; 160(5):1119-27. PubMed ID: 20590605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of exocrine muscarinic receptor binding characteristics and inhibition of salivation of solifenacin in mice.
    Oki T; Takeuchi C; Yamada S
    Biol Pharm Bull; 2006 Jul; 29(7):1397-400. PubMed ID: 16819176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.